DUBLIN--(BUSINESS WIRE)-- <\/p>\n
Research and Markets (http:\/\/www.researchandmarkets.com\/research\/jbqhcr\/global_psoriasis<\/a>) has announced the addition of the \"Global Psoriasis Therapeutics Market 2012-2016\" report to their offering. <\/p>\n The analysts forecast the Global Psoriasis Therapeutics market to grow at a CAGR of 4.06 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing uptake of biologics. The Global Psoriasis Therapeutics market has also been witnessing an increased focus on using combination therapies for treating psoriasis. However, the adverse side effects associated with psoriatic drugs could pose a challenge to the growth of this market. <\/p>\n Commenting on the report, an analyst from the team said: One of the main trends witnessed in the Global Psoriasis Therapeutics market is the increased focus on combination therapies. A current trend witnessed in the Global Psoriasis Therapeutics market is the use of combination therapies for treating psoriasis. Light therapy along with topical treatment products are generally used in combination for the treatment of mild to moderate level of psoriasis. For severe psoriasis oral or injected drugs are used. Due to the severe side effects of these drugs, combination of therapies is used for the effective treatment of severe psoriasis. When the disease is more severe, topic therapy products such as cream is used in combination with oral medications or light therapy. For instance, Anthralin is sometimes used in combination with UV light. Light therapy is also used sometimes in combination with medications. Moreover, in Goeckerman therapy UVB treatment and coal tar treatment is used together as it is more effective than single therapy. <\/p>\n According to the report, one of the main factors driving the market is the increasing uptake of biologics. In recent years the enhanced understanding of the molecular basis underlying psoriasis has led to the introduction of biological drugs, providing a new effective treatment option for this disease. Biologics aim key steps in the pathogenesis of psoriasis and can be categorized into three main categories: TNF alpha inhibitors, T cell inhibitors, and IL-12\/IL-23 inhibitors. <\/p>\n Further, the report states that one of the main challenges is the adverse side effects. Although psoriasis drugs have numerous benefits, they can cause certain harmful side effects. Some of the common side effects caused by various psoriasis drugs are increased risk of skin cancers and lymphomas, hair loss, headache, nausea, and vomiting, suppression of immunity with possible serious infections such as pneumonia or herpes zoster. <\/p>\n Companies Mentioned <\/p>\n - Abbvie Inc. <\/p>\n - Amgen Inc. <\/p>\n - AstraZeneca plc <\/p>\n <\/p>\n Read the original post: DUBLIN--(BUSINESS WIRE)-- Research and Markets (http:\/\/www.researchandmarkets.com\/research\/jbqhcr\/global_psoriasis<\/a>) has announced the addition of the \"Global Psoriasis Therapeutics Market 2012-2016\" report to their offering. The analysts forecast the Global Psoriasis Therapeutics market to grow at a CAGR of 4.06 percent over the period 2012-2016 Continue reading
\nResearch and Markets: Global Psoriasis Therapeutics Market 2012-2016: Detailed Discussion of Trends, Drivers ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"